Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
J Diabetes. 2019 May;11(5):351-358. doi: 10.1111/1753-0407.12878. Epub 2019 Jan 3.
Endoscopic bariatric and metabolic therapies (EBMTs) have sparked significant interest as minimally invasive therapeutic options for weight loss. Although bariatric surgery remains an effective option for sustained weight loss and improvement in the metabolic syndrome, access and utilization are limited. Various EBMTs have been designed to emulate the physiologic effects of established surgical interventions, including space-occupying and non-space-occupying gastric therapies, gastric remodeling procedures, and small bowel therapies. This review discusses the safety and efficacy of available US Food and Drug Administration-approved minimally invasive endoscopic bariatric interventions, as well as those currently under investigation. In addition, the role of endoscopic revision after failed surgical intervention is discussed.
内镜减重与代谢治疗（EBMT）作为一种微创治疗体重减轻的方法，引起了广泛关注。虽然减重手术仍然是一种有效的持续减肥和改善代谢综合征的方法，但它的应用受到限制。各种 EBMT 旨在模拟已确立的手术干预的生理效应，包括占据空间和不占据空间的胃治疗、胃重塑手术和小肠治疗。本文讨论了已获得美国食品和药物管理局批准的微创内镜减重干预措施的安全性和有效性，以及目前正在研究的干预措施。此外，还讨论了手术干预失败后的内镜修正作用。
